Xtant files updated Surgalign historical financials in support of S-3 registration

Xtant Medical Holdings, Inc.

Filing includes Surgalign's unaudited financials for H1 2023 and FY2022, and pro forma combined data for FY2023.
Surgalign H1 2023 revenue $30.3M (down from $41.2M); net income $5.8M vs loss $5.7M, driven by Coflex sale and warrant liability changes.
Pro forma info is presented for informational purposes and does not project future results.
No current operational update or guidance for Xtant is provided in this filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.